Inclusion Criteria:  Healthy infants and young children aged 6-35 months, provide vaccination certificate and birth medical certificate. The subject or legal guardian can provide with informed consent and sign the informed consent form. The subjects or legal guardians are able to and willing to use a thermometer, a scale and fill in a diary card/contact card as required, and be able to comply with the requirements of the clinical trial protocol to complete clinical research.  Exclusion Criteria:  st dose:  Axillary temperature>37.0℃ Participants aged 24-35 months, with abnormal blood routine, blood biochemical and urine routine indexes and judged by the researchers as having clinical significance. Influenza within the past 3 months (confirmed clinically, serologically or microbiological). Have previously received any influenza vaccine (registered or experimental) or planned to receive any influenza vaccine during the study. Allergy to any component of the study vaccine, history of allergic reaction to eating eggs or using gentamicin sulfate. History of severe allergies to any vaccines or drugs. Preterm (delivered before 37 weeks of gestation), low birth weight (birth weight <2500g) infants (only for volunteers aged 6 months to 12 months). Dystocia, suffocation rescue, nervous system damage history. Congenital malformations or developmental disorders affecting organ function, genetic defects, severe malnutrition, etc.. Acute illness, severe chronic illness, or acute exacerbation of chronic illness on the day of vaccination. History of vaccination with the live attenuated vaccine within 14 days prior to vaccination and other vaccination within 7 days. Those receiving immune enhancement or inhibitor therapy within 3 months (continuous oral or infusion for more than 14 days). Have congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, or other autoimmune diseases. History of asthma, unstable in the past two years requiring urgent treatment, hospitalization, intubation, oral or intravenous corticosteroids. Receive blood or blood-related products within 3 months. Have a medical history or family history of convulsion, epilepsy, encephalopathy and psychosis. History of coagulation abnormalities (eg, coagulation factor deficiency, coagulation disorder) Plan to relocate before the end of the study or to be away from home for an extended period of time during scheduled study visits Participating in or planning to participate in other clinical trials in the near future Abnormal laboratory test indicators, except for minor abnormalities that have no clinical significance as judged by the doctor. The investigator judges any situation that is inappropriate to participate in this clinical trial  nd dose:  Severe allergic reaction after the first dose of the vaccine. Serious adverse reactions causally related to the first dose of the vaccine. After the first vaccination, newly discovered or newly occurred do not meet the first-dose inclusion criteria or meet the first-dose exclusion criteria will be determined by the investigator whether to continue participating in the study. Other reasons for exclusion in the opinion of the investigator.